Key result
CETP inhibition is unlikely to be a viable target to treat the most prevalent causes of dementia, such as Alzheimer's disease, and may even modestly increase risk.
Why the study?
Does CETP inhibition reduce the risk of dementia?
Does CETP inhibition reduce the risk of dementia?
Answers are grounded in this paper and cite their sources.
Contrary to previous claims, CETP inhibition is unlikely to be a viable target for treating the most prevalent causes of dementia, such as Alzheimer's disease.
A recent paper concluded that cholesteryl ester transfer protein (CETP) inhibition may be a viable target to treat dementia, based on human genetic evidence of a protective effect of target inhibition on risk of Lewy body and Parkinson's dementia. Alzheimer's disease, which is by far the most prevalent cause of dementia (around 80% of all dementia cases) was not included as an outcome. Evidence shows CETP inhibition is unlikely to affect Alzheimer's risk and may even potentially modestly increase risk. There is also little evidence to support an effect of CETP inhibition on all-cause or vascular dementia. Thus, CETP inhibition is unlikely to be a viable target to treat the most prevalent causes of dementia.
No takes yet. Share an insight, caveat, or question.
Emma L. Anderson (2024) conducted a letter in Dementia. CETP inhibition was evaluated on Risk of dementia (Alzheimer's disease, all-cause, vascular). CETP inhibition is unlikely to be a viable target to treat the most prevalent causes of dementia, such as Alzheimer's disease, and may even modestly increase risk.
Synapse has enriched 10 related papers. Consider them for comparative context: